AstraZeneca (STU:ZEG) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ZEG AstraZeneca PLC STU:ZEG
83 GF Score
Price €140.60
GF Value €156.34
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

STU:ZEG
83GF Score
AstraZeneca PLC STU:ZEG
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (STU:ZEG) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €140.60 is trading 10.1% below its estimated GF Value™ of €156.34. GuruFocus considers AstraZeneca to be Modestly Undervalued.

Key valuation signals for STU:ZEG:

  • Total Noninterest Expense:
  • GF Value™: €156.34 vs. price of €140.60 (10.1% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the STU:ZEG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
83GF Score

Get the complete analysis for STU:ZEG

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€140.60
Price
€156.34
GF Value